您的位置：首页 > 产品中心 > 224624-80-0， CPHPC
CPHPC
产品别名
224624-80-0
CPHPC
Ro 63-8695
(2′R)-Adipoyldi-D-proline
GSK-2315698
1,1′-(1,6-Dioxo-1,6-hexanediyl)bis[D-proline]
R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxohexanoyl]pyrrolidine-2-carboxylic acid
(R)-1-[6-[(R)-2-Carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl-]pyrrolidine-2-carboxylic acid
GSK 2315698
Miridesap
GSK2315698
Ro-63-8695
结构式
基本信息
| Empirical Formula【经验(实验)分子式】 | C16H24N2O6 |
| Molecular weight | 340.37 |
| MDL number | MFCD09970762 |
| Biochem/physiol Actions【生化/生理作用】 | CPHPC (Miridesap; Ro 63-8695) is an orally active serum amyloid P (SAP) blocker that targets the ligand-binding site on the SAP planar binding (B) face with each of its two D-proline moieties (up to two SAP per CPHPC), being able to crosslink and dimerize two SAP pentamers to form B face-to-B face decamers. CPHPC potently inhibits SAP binding to amyloid fibrils in vitro (IC50 = 0.9 μM using AD Aβ amyloid fibrils) and exhibits in vivo efficacy toward liver & circulating SAP clearance as well as SAP removal from tissue amyloid deposits (1-5 mg/mL in drinking water; human SAP transgenic mice). |
产品性质
| Assay【测定】 | ≥98% (HPLC) |
| form【形式】 | powder |
| color【颜色】 | white to beige |
| solubility【溶解性】 | DMSO: 2 mg/mL, clear |
| storage temp.【储存温度】 | −20℃ |
| InChI | 1S/C16H24N2O6/c19-13(17-9-3-5-11(17)15(21)22)7-1-2-8-14(20)18-10-4-6-12(18)16(23)24/h11-12H,1-10H2,(H,21,22)(H,23,24)/t11-,12-/m1/s1 |
| InChI key | HZLAWYIBLZNRFZ-VXGBXAGGSA-N |
安全信息
| Pictograms【象形图】 | GHS07 |
| Signal word【警示用语：】 | Warning |
| Hazard Statements | H302 |
| Precautionary Statements | P264 - P270 - P301 + P312 + P330 - P501 |
| Hazard Classifications【危险分类】 | Acute Tox. 4 Oral |
| Storage Class Code【储存分类代码】 | 13 - Non Combustible Solids |
| WGK | WGK 3 |
